ITCI - Intra-Cellular Therapies Q2 2022 Earnings Preview
- Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open.
- The consensus EPS Estimate is -$0.76 (+10.6% Y/Y) and the consensus Revenue Estimate is $48.62M (+142.5% Y/Y).
- Over the last 1 year, ITCI has beaten EPS estimates 0% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 8 upward revisions and 0 downward. Revenue estimates have seen 7 upward revisions and 1 downward.
For further details see:
Intra-Cellular Therapies Q2 2022 Earnings Preview